Hofseth BioCare ASA

hofsethbiocare.no

Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

SYNTHEGO INTRODUCES CRISPR DISCOVERY PARTNERS TO STREAMLINE CRISPR-DRIVEN DRUG DISCOVERY RESEARCH

Synthego | March 17, 2023

news image

Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery. The CR...

Read More

Cell and Gene Therapy

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab | July 12, 2021

news image

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

news image

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

news image

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More
news image

Industrial Impact, Medical

SYNTHEGO INTRODUCES CRISPR DISCOVERY PARTNERS TO STREAMLINE CRISPR-DRIVEN DRUG DISCOVERY RESEARCH

Synthego | March 17, 2023

Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery. The CR...

Read More
news image

Cell and Gene Therapy

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab | July 12, 2021

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More
news image

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More
news image

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us